Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anavex Life Sciences

8.84
-0.2800-3.07%
Post-market: 8.73-0.1100-1.24%16:42 EDT
Volume:602.29K
Turnover:5.30M
Market Cap:751.97M
PE:-16.00
High:9.09
Open:9.02
Low:8.61
Close:9.12
Loading ...

High Growth Tech Stocks To Watch In The US Market

Simply Wall St.
·
08 Apr

Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years

Benzinga
·
08 Apr

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
07 Apr

Anavex Life Sciences Price Target Maintained With a $42.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Apr

Anavex announces results from Phase IIb/III open-label extension trial

TIPRANKS
·
06 Apr

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results From Phase Iib/Iii Open-Label Extension Trial in Early Alzheimer’s Disease

THOMSON REUTERS
·
05 Apr

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

GlobeNewswire
·
05 Apr

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire
·
31 Mar

Anavex Life Sciences Price Target Maintained With a $42.00/Share by HC Wainwright & Co.

Dow Jones
·
31 Mar

Beat the Market the Zacks Way: Amgen, DRDGOLD, Anavex in Focus

Zacks
·
17 Mar

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
07 Mar

Analysts Offer Insights on Healthcare Companies: Anavex Life Sciences (AVXL) and Applied DNA Sciences (APDN)

TIPRANKS
·
28 Feb

When Will Anavex Life Sciences Corp. (NASDAQ:AVXL) Breakeven?

Simply Wall St.
·
26 Feb

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

GlobeNewswire
·
24 Feb

Stock Track | Anavex Life Sciences Soars 5.16% on Analyst's Buy Rating and European Growth Outlook

Stock Track
·
18 Feb

Buy Rating for Anavex Life Sciences Due to Solid Financials and European Market Potential

TIPRANKS
·
18 Feb

Anavex Life Sciences Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
12 Feb

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
12 Feb

Stock Track | Anavex Life Sciences Soars 5.55% Pre-Market on Upbeat Q1 Results, Patent Win for Alzheimer's Drug

Stock Track
·
12 Feb

Anavex Life Sciences Q1 2025 GAAP EPS $(0.14) Beats $(0.19) Estimate, Cash And Cash Equivalents Of $120.8M At December 31, 2024, The Company Anticipates At Current Cash Utilization Rates And Ranges, A Runway Of Approximately 4 Years

Benzinga
·
12 Feb